The Canadian cannabis stocks we’ve identified offer future value for investors through their innovative patented technologies and products
SmallCapPower | August 28, 2018: Today we have highlighted five Canadian cannabis stocks that have developed novel cultivation techniques and cannabis-related products. Upon recreational legalization in Canada on October 17, cannabis companies will face fierce competition, but these companies are primed to distinguish themselves through their patent-protected products. In general, the returns on cannabis stocks during the past two weeks have been robust. On average, the top 10 marijuana companies by market cap have been up 37% over the past month, with Canopy Growth Corp (TSX:WEED) leading the charge with a 79% surge.
For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
Watch: Cannex Capital Holdings (CSE:CNNX) Wants to Emerge as a Multi-State U.S. Player, Says CEO
Aurora Cannabis Inc. (TSX:ACB) – $9.25
Cannabis
Aurora Cannabis is a licensed producer and seller of medical marijuana and cannabis oil under the ACMPR. On April 16, 2018, Aurora announced an agreement with CTT Pharmaceutical Holdings Incorporated (OTC:CTTH) for joint exclusive rights for the Canadian distribution of CTT’s patented drug delivery technologies. The agreement includes rights to six patents related to cannabis delivery technologies, including the Orally Dissolvable Thin Film (ODF) Wafer technology. ODF Wafers are taken orally and dissolve quickly in the mouth, allowing for easy consumption of cannabis especially for individuals who have difficulty swallowing.
- Market Cap: $8,780 Million
- 1 Month Total Return: 20.8%
- 52 Week Total Return: 253.5%
- Avg Volume last 30 days: 15,340,749
Hydropothecary Corp. (TSX:HEXO) – $5.65
Cannabis
Hydropothecary is a Canadian cannabis producer, operating a 50,000 sq. ft. grow facility in Quebec. The Company differentiates itself through its commitment to natural growth techniques and a focus on customer service. Current operations produce 3,600 kg of cannabis per year. The Company is the only licensed products of the Decarb product line, a powder medical marijuana that offers consumers a safe and easy way to consume cannabis. On August 1, 2018, Hydropothecary formed a joint venture with Molson Coors Brewing Company (TSX:TPX, NYSE:TAP) to developed non-alcoholic, cannabis-infused beverages following the legalization of the consumable cannabis market in 2019.
- Market Cap: $1,120 Million
- 1 Month Total Return: 23.3%
- 52 Week Total Return: 291.9%
- Avg Volume last 30 days: 2,627,314
Delta 9 Cannabis Inc. (TSXV:NINE) – $1.54
Cannabis
Delta 9 is a Winnipeg-based licensed producer of medical cannabis that develops over 20 different strains for the Canadian market. Current operations include an 80,000 sq. ft. production facility. In July 2018, Delta 9 reached a licensing agreement with Nanosphere Health Sciences (CSE:NSHS), which granted Delta 9 a license to use Nanosphere’s patented delivery system technology in Canada. The technology utilizes nanoparticles to deliver cannabis into the circulatory system and relieving pain, anxiety, and inflammation. As per the agreement, Delta 9 is permitted to subcontract the patent to other providers in Canada.
- Market Cap: $122.8 Million
- 1 Month Total Return: 46.7%
- 52 Week Total Return: 670%
- Avg Volume last 30 days: 103,638
RavenQuest Biomed Inc. (CSE:RQB) – $0.64
Cannabis
RavenQuest Biomed is a diversified cannabis company with divisions focused upon cannabis production, management services and specialized research & development. Currently, the Company owns two cultivation facilities with an estimated production capacity of 11,000 kg/year. In November 2017, the Company entered into a research partnership with Montreal’s McGill University to research topics including plant stabilization and yield improvements. As part of this agreement, RavenQuest gained access to head researcher Dr. Donald Smith’s patented technologies for increasing crop yields.
- Market Cap: $59.9 Million
- 1 Month Total Return: 34.0%
- 52 Week Total Return: 1300.0%
- Avg Volume last 30 days: 416,729
Canntab Therapeutics Ltd. (CSE:PILL) – $0.65
Cannabis
Canntab Therapeutics is a cannabis technology company focused on developing innovative delivery systems for cannabis products. The Company has developed a diverse product line of solid oral delivery systems capable of providing a variety of THC and CBD blends in exact dosages. In 2017, Canntab entered into a licensing agreement with Emblem Corp. (TSXV:EMC), giving Emblem the rights for development and sale of Canntab products within Canada. The Company currently has 13 patents pending.
- Market Cap: $15.9 Million
- 1 Month Total Return: -13.2%
- 52 Week Total Return: -67.0%
- Avg Volume last 30 days: 23,777.4
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
